RetinAI Medical AG is a Swiss company specialized in software solutions that accelerate clinical, research and pharmaceutical workflows, with a focus on retinal diseases. RetinAI’s disease evaluation apps consist of a set of CE-marked AI models approved for clinical and research use only. These models include fluid and layer segmentation, macular biomarker detection, and GA progression prediction to support your diagnosis and research on nAMD, dAMD, DR/DME, CME & GA. 

Abyss Processing’s Reflectivity, now available through Heidelberg AppWay, delivers advanced optic nerve head analysis powered by AI. From a single OCT scan, it provides detailed 3D optic nerve head analysis, lamina cribrosa parameters, and a precise glaucoma risk score. Additionally, the report offers detailed information regarding the quality of the AI-based segmentation, ensuring that healthcare professionals have access to the most valuable insights for patient care and assessment.

Altris AI transforms OCT scan analysis into a reliable decision-support tool for eye care specialists. CE-certified, HIPAA and GDPR-compliant, and FDA-cleared (510K), it detects 70+ pathologies and biomarkers, including assessment of glaucoma risk. The platform streamlines workflow with automated triage, vendor-neutral OCT comparisons, and customizable reports - helping clinicians make faster, more precise diagnostic and treatment decisions.

deepeye® TPS is the first CE-marked predictive AI assistant for IVI therapy planning in nAMD. Designed to improve efficiency and effectiveness, the AI then analyzes pseudonymized scans and generates a report including:

• Assessment of disease activity for one-glance therapy decision support.
• Biomarker visualization for explainability of AI recommendation.
• 12-month therapy need prognosis to support patient education.
• Trend diagrams on therapy progress.
• Text summary for accelerated documentation.

A groundbreaking AI-based software to accelerate the genetic diagnosis of inherited retinal diseases, based on SPECTRALIS imaging. The research project focuses on inherited retinal diseases and aims to provide clinicians with in-depth genetic insights. By analyzing retinal scans, clinicians may be able to identify the specific gene responsible for the inherited condition, leading to a more accurate diagnosis and personalized treatment for patients.

GA Grader is an AI-powered tool developed by the GRADE Reading Center to provide precise, objective assessment of geographic atrophy (GA) secondary to AMD. Based on analysis of imported SPECTRALIS OCT imaging data, it delivers automated lesion segmentation, accurate quantification of atrophy size and progression, and intelligent fovea detection for enhanced reliability of disease progression tracking and a clearer understanding of the impact on central vision. GA Grader offers standardized reports with visual overlays, trend comparisons, and structured data output to support both clinical care and research studies.

NetraMind Innovations, Inc. is an AI-driven image analysis company founded by leading retinal specialists and engineers with over 50 years of combined expertise in ophthalmic imaging and computational analysis. Its flagship solution, NMI-ChoroidAI, delivers fully automated choroidal assessment from SPECTRALIS® OCT scans. Using advanced machine learning, it provides precise 3D segmentation of inner and outer choroidal boundaries, quantifies thickness, volume, and the Choroidal Vascularity Index (CVI), and generates reproducible, comprehensive reports.

RetinaLyze® is a CE-certified, AI-powered eye screening software that analyzes fundus images and OCT scans to detect signs of diabetic retinopathy, AMD, glaucoma, and other pathologies. Delivering instant, reproducible results, it can be used as a clinical decision support system or with a telemedicine module. Trusted in hospitals, clinics, and optical chains worldwide with over 6 million screenings performed, RetinaLyze helps clinicians save time, standardize care, and prevent avoidable vision loss. 

RetInSight offers MDR CE-certified AI solutions for OCT imaging. GA Monitor supports clinical routine by identifying disease activity and therapeutic response in geographic atrophy, making the invisible visible through visualization and quantification of PR degeneration and RPE loss. Fluid Monitor quantifies and visualizes fluid dynamics in nAMD, enabling an objective, reliable assessment that replaces subjective evaluation in daily practice.